Analysts expect resTORbio, Inc. (NASDAQ:TORC) to report earnings of ($0.41) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for resTORbio’s earnings, with estimates ranging from ($0.42) to ($0.40). resTORbio posted earnings per share of ($0.48) during the same quarter last year, which indicates a positive year over year growth rate of 14.6%. The company is expected to announce its next earnings report on Thursday, August 8th.
On average, analysts expect that resTORbio will report full year earnings of ($1.84) per share for the current year, with EPS estimates ranging from ($1.90) to ($1.74). For the next financial year, analysts expect that the firm will report earnings of ($2.31) per share, with EPS estimates ranging from ($2.55) to ($2.13). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover resTORbio.
resTORbio (NASDAQ:TORC) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.02).
A number of research firms have issued reports on TORC. Zacks Investment Research raised shares of resTORbio from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a research note on Tuesday. Guggenheim began coverage on shares of resTORbio in a report on Tuesday, June 4th. They issued a “buy” rating and a $28.00 target price on the stock. Svb Leerink reiterated an “outperform” rating on shares of resTORbio in a report on Monday, March 25th. Finally, Wedbush restated an “outperform” rating on shares of resTORbio in a report on Monday, March 18th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. resTORbio presently has an average rating of “Buy” and an average target price of $18.88.
A number of large investors have recently added to or reduced their stakes in TORC. Vanguard Group Inc. lifted its stake in resTORbio by 2.7% in the 3rd quarter. Vanguard Group Inc. now owns 288,490 shares of the company’s stock worth $4,368,000 after purchasing an additional 7,545 shares in the last quarter. Vanguard Group Inc grew its stake in shares of resTORbio by 2.7% in the third quarter. Vanguard Group Inc now owns 288,490 shares of the company’s stock worth $4,368,000 after acquiring an additional 7,545 shares in the last quarter. Segantii Capital Management Ltd grew its stake in shares of resTORbio by 54.5% in the fourth quarter. Segantii Capital Management Ltd now owns 741,816 shares of the company’s stock worth $6,394,000 after acquiring an additional 261,630 shares in the last quarter. BlackRock Inc. grew its stake in shares of resTORbio by 70.7% during the fourth quarter. BlackRock Inc. now owns 802,683 shares of the company’s stock worth $6,920,000 after purchasing an additional 332,423 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in resTORbio by 9.9% in the fourth quarter. Bank of New York Mellon Corp now owns 27,788 shares of the company’s stock valued at $239,000 after acquiring an additional 2,497 shares in the last quarter. Hedge funds and other institutional investors own 52.43% of the company’s stock.
Shares of NASDAQ TORC traded up $0.18 during midday trading on Friday, hitting $8.52. The company’s stock had a trading volume of 505 shares, compared to its average volume of 130,536. resTORbio has a 1-year low of $6.21 and a 1-year high of $20.59. The firm has a market capitalization of $300.96 million, a PE ratio of -5.85 and a beta of 2.83.
resTORbio Company Profile
resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems.
Read More: What is meant by a buy rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.